Who are IFN beta(24 weeks)'s main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Besremi, Saphnelo, Gamifant, Plegridy, Avonex, Betaseron.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/ifn-beta-24-weeks.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

IFN beta(24 weeks) — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

IFN beta(24 weeks) (IFN beta(24 weeks)) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Interferon. Area: Immunology.

phase 3 Interferon Interferon-alpha/beta receptor (IFNAR) Immunology Small molecule Live · refreshed every 30 min

Target snapshot

IFN beta(24 weeks) (IFN beta(24 weeks)) — Tanabe Pharma Corporation. Interferon beta activates innate immune responses by binding to interferon-beta receptors on immune cells, enhancing antiviral and immunomodulatory activity.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
IFN beta(24 weeks) TARGET	IFN beta(24 weeks)	Tanabe Pharma Corporation	phase 3	Interferon	Interferon-alpha/beta receptor (IFNAR)
Besremi	ROPEGINTERFERON ALFA-2B	Pharma Essentia Corporation	marketed	Interferon alfa-2b [EPC]	Interferon alpha/beta receptor	2021-01-01
Saphnelo	ANIFROLUMAB	AstraZeneca	marketed	Type I Interferon Receptor Antagonist [EPC]	Interferon alpha/beta receptor 1	2021-01-01
Gamifant	EMAPALUMAB	Novimmune S.A.	marketed	Interferon gamma Blocker [EPC]	Interferon gamma	2018-01-01
Plegridy	PEGINTERFERON BETA-1A	Biogen Idec Inc	marketed	Interferon beta [EPC]	Interferon alpha/beta receptor	2014-01-01
Avonex	INTERFERON BETA-1A	Biogen	marketed	Interferon beta [EPC]	Interferon alpha/beta receptor	1996-01-01
Betaseron	INTERFERON BETA-1B	Bayer Healthcare Pharms	marketed	Interferon beta	Interferon alpha/beta receptor	1993-01-01

Recent regulatory actions (last 90 days)

2026-04-24 — Saphnelo · FDA · approved · US · AstraZeneca

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Interferon class)

EMD Serono · 3 drugs in this class
Cinnagen · 2 drugs in this class
Tanabe Pharma Corporation · 2 drugs in this class
Biogen · 1 drug in this class
Celgene · 1 drug in this class
EMD Serono Research & Development Institute, Inc. · 1 drug in this class
Case Comprehensive Cancer Center · 1 drug in this class
Hoffmann-La Roche · 1 drug in this class
Human Genome Sciences Inc. · 1 drug in this class
Bayer · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). IFN beta(24 weeks) — Competitive Intelligence Brief. https://druglandscape.com/ci/ifn-beta-24-weeks. Accessed 2026-06-10.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing